- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07614542
AGEWISE: Unravelling the Gut-Hormone Axis in Women's Ageing
Studieöversikt
Status
Detaljerad beskrivning
AGEWISE aims to investigate the relationship between the gut microbiome, female sex hormones, chronic low-grade inflammation, and women's ageing across the menopausal transition.
The results will support the identification of microbiome-based and blood-based biomarkers associated with menopause and ageing, and contribute to the development of data-driven tools for personalised risk assessment and prevention strategies in women's health.
Primary Objective:
To identify and validate faecal microbiome biomarkers by analysing taxonomic and functional changes across different stages of menopause in women.
Secondary Objectives:
To explore associations between gut microbiome composition and female sex hormone levels, including estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and cortisol.
To investigate the relationship between the gut microbiome and blood biomarkers of chronic low-grade inflammation (inflammaging).
To assess associations between microbiome profiles, clinical history, lifestyle, and dietary factors and the risk of conditions associated with menopause.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Ana S Almeida, PhD
- Telefonnummer: +351 217999411
- E-post: ana.almeida@gimm.pt
Studera Kontakt Backup
- Namn: Madalena Reis
- Telefonnummer: +351 217999411
- E-post: madalena.reis@gimm.pt
Studieorter
-
-
-
Lisbon, Portugal
- Rekrytering
- Gulbenkian Institute for Molecular Medicine, Lisbon
-
Kontakt:
- Ana S Almeida, PhD
- Telefonnummer: +351 217999411
- E-post: ana.almeida@gimm.pt
-
Kontakt:
- Madalena Reis
- Telefonnummer: +351 217999411
- E-post: madalena.reis@gimm.pt
-
Huvudutredare:
- Ana S Almeida, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Female sex
- Aged 40 to 64 years
- Resident in mainland Portugal or the islands
- Able and willing to provide written informed consent
- Willing to provide stool and blood samples and complete three questionnaires
Exclusion Criteria:
- Age below 40 years or 65 years and older
- Inability to give informed consent
- Refusal to provide stool or blood samples or complete questionnaires
- Pregnancy
- Diagnosed gastrointestinal disorders (including inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, chronic diarrhoea of unknown cause, or recurrent Clostridioides difficile infection)
- Active oncological disease
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Premenopausal women (self-reported)
Regular menstrual periods, with no signs of menopause yet.
|
|
Perimenopausal women (self-reported)
Irregular menstrual periods, presence of some menopausal symptoms, such as hot flashes, mood changes, sleep disturbances, and brain fog.
|
|
Menopausal/Postmenopausal women (self-reported)
Absence of menstruation for 12 consecutive months.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Gut microbiome functional profile.
Tidsram: Baseline and every 2 years over a period of 10 years.
|
Changes in microbial gene functions and metabolic pathways derived from metagenomic analysis.
|
Baseline and every 2 years over a period of 10 years.
|
|
Gut microbiome taxonomic composition
Tidsram: Baseline and 2 years over a period of 10 years.
|
Changes in faecal microbiome composition assessed by shotgun metagenomic sequencing across menopause stages.
|
Baseline and 2 years over a period of 10 years.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Female sex hormone levels.
Tidsram: Baseline and every 2 years over a period of 10 years.
|
Blood levels of estradiol, FSH, LH, AMH, and cortisol measured by immunoassays.
|
Baseline and every 2 years over a period of 10 years.
|
|
Inflammation biomarker levels.
Tidsram: Baseline and every two years over a period of 10 years.
|
Blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β) and TNF-α.
|
Baseline and every two years over a period of 10 years.
|
|
Menopause-related symptoms
Tidsram: Baseline and every two years over a period of 10 years.
|
Self-reported menopausal symptoms will be assessed via online questionnaires that include reproductive, medical history and associated symptoms.
|
Baseline and every two years over a period of 10 years.
|
|
Nutritional data
Tidsram: Baseline and every two years over a period of 10 years.
|
Self-reported dietary intake will be assessed via telephone interview through two 24-hour recalls, following protocols validated by the Portuguese National Food and Physical Activity Survey (IAN-AF).
|
Baseline and every two years over a period of 10 years.
|
|
Effect of physical activity on gut microbiota composition
Tidsram: Baseline and every two years over a period of 10 years.
|
Physical activity will be assessed using International Physical Activity Questionnaire - Short Form a validated tool composed of 7 questions covering the last 7 days of physical activity across three intensity levels which allows classification of participants into three activity levels: low, moderate, or high.
|
Baseline and every two years over a period of 10 years.
|
|
Effect of sleeping habits on gut microbiota composition
Tidsram: Baseline and every 2 years over a period of 10 years.
|
Sleeping habits will be assessed by the Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire that consists of 19 items which are distributed into seven "components": subjective sleep quality; sleep latency; sleep duration; habitual sleep efficiency; sleep disturbances; use of sleeping medication; day-time dysfunction.
Each component is scored from 0 to 2, and the sum of the component scores yields a global PSQI score.
A global PSQI score ≥6 will indicate poor sleep quality.
|
Baseline and every 2 years over a period of 10 years.
|
|
Effect of stress levels on gut microbiota composition
Tidsram: Baseline and every 2 years over a period of 10 years.
|
Stress levels will be assessed by the Perceived Stress Scale, a validated questionnaire composed of 10 questions.
Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.
Scores ranging from 0-13 will be considered low stress, 14-26 will be considered moderate stress and scores ranging from 27-40 will be considered high perceived stress.
|
Baseline and every 2 years over a period of 10 years.
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- CAML Ref nº188/25
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .